Skip to content

High Flow Nasal Oxygen Therapy in COVID-19 patients

High Flow Nasal Oxygen Therapy in COVID-19 patients : A cross-sectional study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/030015
Enrollment
108
Registered
2020-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NIL: NIL

Sponsors

All India Institute of Medical Sciences Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Patients tested COVID-19 positive by Reverse Transcriptase Polymerase Chain Reaction (rt-PCR) test and admitted in Corona Critical Care wards at AIIMS, Jodhpur till January 31, 2021 - Requiring the use of High FLow Nasal Oxygen Therapy

Exclusion criteria

Exclusion criteria: - Patients who / whose proxies refuse to consent to use of their data for research - Patients who were on non-invasive / invasive mechanical ventilation before the use of HFNC (High Flow Nasal Cannula)

Design outcomes

Primary

MeasureTime frame
The number of patients who did not require intubation and invasive mechanical ventilation by using HFNC as a rescue modality to manage hypoxemia in rt-PCR confirmed Covid-19 patients admitted to the critical care settingTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached

Secondary

MeasureTime frame
The 28 days all-cause mortality and length of ICU/CCCU stay in these patientsTimepoint: Time of discharge and 28 days post admission;The blood gas parameters (Po2 and PFR) of patients taken on HFNC and their trends over time of useTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached;The duration of HFNC requiredTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached;The validity of using ROX and modified ROX indices as a predictor of intubation and hence failure of HFNCTimepoint: 2hrs, 6hrs, 12hrs and subsequently at 24hr intervals post initiating HFNC use;To compare the data among various demographics and patients with varied comorbiditiesTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached

Countries

India

Contacts

Public ContactDr Samarth Agarwal

All India Institute of Medical Sciences, Jodhpur

samarthx@gmail.com8932938707

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026